SCHEDULE 13D/A: Scilex Holding Co Secures Debt Payment Deferral by Transferring 5 Million Shares

Sentiment:

Schedule 13D Amendment 7 January 2025 12:11 AM

Scilex Holding Company and its guarantor, SCLX Stock Acquisition JV LLC, have successfully deferred a significant Tranche B Notes amortization payment until October 2026, in exchange for a cash payment and the transfer of 5 million common shares by the guarantor to noteholders.

Delay expectedThe Issuer's obligation to make the First Amortization Payment of $6,250,000 on the Tranche B Notes, originally due January 2, 2025, was initially deferred to January 31, 2025.This payment was subsequently further deferred until October 8, 2026, contingent on a $1.11 million payment by the Issuer and the transfer of 5,000,000 shares by the Reporting Person.

Worse than expectedThe company required a deferral of a scheduled debt payment, indicating potential liquidity issues or financial strain.Significant consideration, including a cash payment and the transfer of 5,000,000 shares by a guarantor, was required to secure the deferral, highlighting the cost of managing debt obligations.

Summary

Scilex Holding Company (the "Issuer") was obligated to make a $6,250,000 cash amortization payment on its Tranche B Senior Secured Convertible Notes on January 2, 2025.
The Issuer and SCLX Stock Acquisition JV LLC (the "Reporting Person"), a guarantor, entered into deferral and consent letters with the Tranche B Noteholders (Oramed Pharmaceuticals Inc., Nomis Bay Ltd, BPY Limited, and 3i, LP).
Initially, the noteholders agreed to defer the First Amortization Payment until January 31, 2025.
In consideration for this initial deferral and to limit secured creditor remedies against the Reporting Person's assets, the Reporting Person delivered an aggregate of 5,000,000 shares of Common Stock to the noteholders.
A further deferral of the First Amortization Payment was agreed upon until October 8, 2026, contingent on the Issuer paying an aggregate of $1.11 million, which has been paid.
The Reporting Person, SCLX Stock Acquisition JV LLC, beneficially owns 84,616,299 shares of Scilex Holding Co, representing 22.8% of the Common Stock outstanding.
This beneficial ownership includes 55,068,585 shares of Common Stock, 490,617 shares issuable upon warrant exercise, and 29,057,097 shares of Series A Preferred Stock (entitled to 32,596,371 votes).
The Reporting Person's aggregate voting power, including preferred stock votes and warrants, is 31.89%.

Sentiment

Score: 3

Explanation: The need to defer a debt payment, even with a successful negotiation, suggests underlying financial challenges. The cost of deferral, including a cash payment and the transfer of a significant number of shares, indicates a less than ideal financial position. While a default was avoided, the circumstances are not positive.

Positives

The Issuer successfully deferred a significant $6.25 million debt amortization payment, alleviating immediate cash flow pressure.
The deferral agreement limits the Tranche B Noteholders' right to exercise certain secured creditor remedies against the Reporting Person's assets, providing a temporary reprieve from potential enforcement actions.

Negatives

The deferral came at a cost, requiring the Issuer to pay $1.11 million and the Reporting Person to transfer 5,000,000 shares of Common Stock to the noteholders.
The transfer of 5,000,000 shares by the Reporting Person represents a significant asset transfer to secure the deferral, indicating financial strain.

Risks

The need to defer a scheduled debt payment suggests ongoing financial challenges or liquidity constraints for Scilex Holding Co.
Failure to meet the deferred payment obligation by October 8, 2026, could lead to the exercise of secured creditor remedies by the Tranche B Noteholders.
The transfer of 5,000,000 shares by the Reporting Person to noteholders could be perceived negatively by the market, potentially impacting investor confidence.

Future Outlook

The Issuer's obligation to make the First Amortization Payment on the Tranche B Notes has been further deferred until October 8, 2026, provided the agreed-upon cash payment has been made.

Industry Context

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Amendment to Subsidiary Guarantee	The Subsidiary Guarantee was amended on October 8, 2024, to include the obligations under the Tranche B Notes, in addition to the Tranche A Note and Additional Notes.	2024-10-08	Expands the scope of the guarantee provided by the Issuer's subsidiaries, including the Reporting Person, to cover new debt obligations, increasing their financial exposure.
Amendment and Restatement of Security Agreement	The Security Agreement was amended and restated on October 8, 2024, to grant a security interest in substantially all property of the Issuer and Guarantors to secure obligations under the Tranche B Notes, in addition to previously secured Tranche A Notes and Additional Notes.	2024-10-08	Broadens the collateral base for the Tranche B Noteholders, providing them with stronger recourse against the company's assets in case of default.

Stakeholder Impact

Shareholders: The transfer of 5,000,000 shares by the Reporting Person (a significant shareholder) to noteholders could be perceived as a negative signal regarding the company's financial health, potentially impacting share price.
Creditors (Tranche B Noteholders): While their immediate payment was deferred, they received consideration in the form of shares and a cash payment, and their security interest was broadened, potentially strengthening their position in the long term despite the delay.

Next Steps

The Issuer is now obligated to make the deferred First Amortization Payment on the Tranche B Notes by October 8, 2026.

Key Dates

Date	Description
2022-11-10	Delaware Secretary of State filing date for the Issuer's Certificate of Designations of Series A Preferred Stock.
2023-09-21	Date of original Subsidiary Guarantee and Security Agreement entered into by the Issuer and Guarantors with Oramed and Acquiom Agency Services LLC.
2023-09-29	Original Schedule 13D filing date with the SEC.
2024-10-08	Date Tranche B Senior Secured Convertible Notes were issued; also date of Subsidiary Guarantee Amendment and Amended and Restated Security Agreement.
2024-12-29	Date as of which 243,312,885 shares of Common Stock were outstanding for percentage calculation.
2025-01-02	Original First Amortization Payment Date for Tranche B Notes; also date of deferral and consent letters.
2025-01-06	Date of filing of Amendment No. 4 to Schedule 13D.
2025-01-31	Initial deferred First Amortization Payment Date.
2026-10-08	Further deferred First Amortization Payment Date for Tranche B Notes.

Recommendation

sell

Keywords

Scilex Holding Co, SCLX, Schedule 13D, debt deferral, convertible notes, Tranche B Notes, beneficial ownership, stock transfer, corporate finance, Oramed Pharmaceuticals, Nomis Bay Ltd, BPY Limited, 3i LP

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.